In this free webinar, the featured speakers will discuss in vitro verification of product function and animal model selection in preclinical studies. Attendees will learn about pharmacology and toxicity studies to guide determination of biologically relevant and clinically safe dose levels, as well as the biological disposition of product including tumor cell infiltration, persistence and viral shedding.
TORONTO (PRWEB) June 02, 2020
Adoptive cell therapies have ushered in a paradigm shift in the treatment of cancers with the watershed FDA approvals of two Chimeric Antigen Receptor T-Cell (CAR-T) therapies in 2017. In addition to CAR-Ts, other cell-based immunotherapies in development have emerged including modified T-cell receptor T-cells (TCR-Ts), Natural Killer (NKs) cells and Dendritic Cells (DCs).
In this webinar, presenters will discuss aspects of an adoptive cell therapy preclinical program that are central to an IND/IMPD submission – namely, in vitro and in vivo pharmacology, toxicology and pharmacokinetics (PK) assessments using the appropriate models & test systems. Together, these studies help to guide determination of clinically safe and biologically relevant dose levels, establish safety endpoints for clinical study monitoring and elucidate the biological disposition of administered cell product.
Join Maryland Franklin, PhD, Executive Director of Scientific Development, Preclinical Oncology, Covance and Brian E. McIntosh, PhD, Study Director and Scientific Lead Cell, Gene and Regenerative Therapies, Covance in a live webinar on Thursday, June 18, 2020 at 10am EDT (3pm BST/UK).
For more information or to register for this event, visit IND-Enabling Programs for Adoptive Cell Therapies.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
This webinar is part of a scientific series Covance is offering focused on trends, opportunities and challenges associated with current and future applications in Oncology. Learn more and register for upcoming webinars on topics such as adoptive cell therapies, biomarker technologies for the detection of cancer driver mutations, novel targeted therapies, and more.
To learn more about Xtalks, visit http://xtalks.com.
For information about hosting a webinar, visit http://xtalks.com/why-host-a-webinar/.
For the original version on PRWeb visit: https://www.prweb.com/releases/ind_enabling_programs_for_adoptive_cell_therapies_upcoming_webinar_hosted_by_xtalks/prweb17161741.htm